Pulmonary Condensate: Non-invasive Evaluation of Pulmonary Involvement in Asthma and Cystic Fibrosis.

Conditions studied

Bronchial Asthma, Pulmonary Cystic Fibrosis

About this study

Exhaled breath condensate (EBC) represents a rich source for countless biomarkers that can provide valuable information about respiratory as well as systemic diseases. Finding non-invasive methods for early detection of lung injury, inflammation and infectious complications in chronic diseases like (CF) Cystic fibrosis or (AB) Bronchial asthma would be highly beneficial. Investigators propose to establish EBC "breathprints" revealing molecular signatures of pulmonary inflammation and specific respiratory bacterial infections of CF patients and AB. Investigators hypothesize that the analysis of EBC can reveal biomarkers specific for severity of the inflammation, and infection caused by opportunistic pathogens such as P. aeruginosa (PA). With these breath-prints, investigators also propose to establish correlations between respiratory microbiota using traditional methods and CF lung disease severity. Together, the studies will advance the development and validation of EBC as a novel tool for the proper diagnosis of AB and monitoring of CF disease activity, treatment efficacy and PA or another opportunistic infections.

Interventions

• Diagnostic Test: Collection of breath condensate — Breath condensate will be collected from the patients involved in study.

Primary outcomes

• Biomarker identification using method of High Resolution Mass Spectrometry processed on Orbitrap Velos Elite machine (18 months from the screening)
• FEV1 determination in Cystic Fibrosis patients (18 months from the screening)
• FVC determination in Cystic Fibrosis patients (18 months from the screening)
• Amylase readings in blood serum in Cystic Fibrosis patients (18 months from the screening)
• Lipase readings in blood serum in Cystic Fibrosis patients (18 months from the screening)
• Microbiology cultivation in Cystic Fibrosis patients (18 months from the screening)
• CT in Cystic Fibrosis patients (18 months from the screening)
• RTG in Cystic Fibrosis patients (18 months from the screening)

Eligibility information

Study locations

• University Hospital Olomouc, Olomouc, 77900 Czechia